Products Most statins are commercially available in the form of film-coated tablets, and some are also available as capsules. The first active ingredient to be marketed was lovastatin from Merck in the United States in 1987. In many countries, simvastatin (Zocor) and, shortly thereafter, pravastatin (Selipran) were the first agents to be approved in 1990. … Statins
Products Medicinal mushrooms are commercially available, for example, in the form of capsules, tablets and as powders as dietary supplements or as individually prepared mixtures. Also used are the pure ingredients that are extracted, synthetically produced or semi-synthetically modified. These are usually registered as medicinal products. About mushrooms Fungi are a very diverse group of … Medicinal Mushrooms
Products Evolocumab was approved in the EU and US in 2015 and in many countries in 2016 in the form of a solution for injection (Repatha). Structure and properties Evolocumab is a human IgG2 monoclonal antibody with a molecular mass of 141.8 kDa. It is produced by biotechnological methods. Effects Evolocumab (ATC C10AX13) has lipid-lowering … Evolocumab
Products Ezetimibe is commercially available in tablet form, as a monopreparation (Ezetrol, generic), and as a fixed combination with simvastatin (Inegy, generic) and with atorvastatin (Atozet). Also released is a combination with rosuvastatin. Ezetimibe was approved in many countries and in the United States in 2002. Generic and auto-generics entered the market in November 2017. … Ezetimibe
Products Colestipol is commercially available as granules (Colestid). It has been approved in many countries since 1978. Structure and properties Colestipol is present in drugs as colestipol hydrochloride. It is a basic, high-molecular-weight anion-exchange resin. Effects Colestipol (ATC C10AC02) has lipid-lowering (LDL) properties by binding bile acids in the intestine and delivering them to excretion. … Colestipol
Products Lipid-lowering agents are mainly sold as tablets and capsules as monopreparations and combination preparations. Some other dosage forms exist, such as granules and injectables. Statins have established themselves as the most important group at present. Structure and properties The chemical structure of lipid-lowering agents is inconsistent. However, within the class, groups with comparable structures … Lipid-Lowering Agents
Products Pravastatin is commercially available in tablet form (Selipran, generics). It has been approved in many countries since 1990. Structure and properties Pravastatin (C23H36O7, Mr = 424.5 g/mol) is present in drugs as pravastatin sodium, a white to yellowish-white powder or crystalline powder that is readily soluble in water. It is not a prodrug, unlike … Pravastatin
Products Gemfibrozil is commercially available in the form of film-coated tablets (Gevilon, Gevilon Uno). It has been approved in many countries since 1985. Structure and properties Gemfibrozil (C15H22O3, Mr = 250.3 g/mol) exists as a white powder that is practically insoluble in water. Effects Gemfibrozil (ATC C10AB04) has lipid-lowering properties. It lowers VLDL, triglycerides, total … Gemfibrozil
Effects Glitazars combine the lipid-lowering effects of fibrates (lower triglycerides and LDL, increase HDL) with the antidiabetic effect of glitazones, which increase tissue sensitivity to insulin. Mechanism of action Glitazars have a dual mechanism of action. On the one hand, they activate the nuclear receptor PPAR-alpha, the drug target of fibrates, and on the other … Glitazare
Active ingredients Insulins substitute for endogenous insulin: Human insulin Insulin analogues Biguanides reduce hepatic glucose formation: Metformin (Glucophage, generic). Sulfonylureas promote insulin secretion from beta cells: Glibenclamide (Daonil, generic). Glibornuride (Glutril, off label). Gliclazide (Diamicron, generic). Glimepiride (Amaryl, generics) Glinides promote insulin secretion from beta cells: Repaglinide (NovoNorm, generic). Nateglinide (Starlix) Glitazones decrease peripheral insulin … Antidiabetics
Effects Fibrates (ATC C10AB) have lipid-lowering properties. They primarily lower elevated blood triglyceride levels and have a moderate effect on LDL cholesterol and slightly increase HDL. The effects are due to activation of nuclear receptors PPAR (mainly PPARα). Indications Blood lipid disorders, especially hypertriglyceridemia. Agents Bezafibrate (Cedur retard) Fenofibrate (Lipanthyl) Fenofibric acid (Trilipix) Gemfibrozil (Gevilon) … Fibrate
Products Nicotinic acid was commercially available in the form of modified-release tablets as a fixed combination with laropiprant (Tredaptive, 1000 mg/20 mg). The combination was approved in many countries in 2009, replacing earlier monopreparations such as Niaspan. The drug was withdrawn from the market on January 31, 2013. Structure and properties Nicotinic acid (C5H5NO2, Mr … Nicotinic Acid
